Collaboration to target drugs for ovarian cancer

Toronto, ON May 1, 2003 Medical biotechnolgy company Arius Research says it is entering into a collaboration with the Ottawa Regional Cancer Centre (ORCC) to study a group of cancer killing antibodies in specialized models of human ovarian cancer.

Researchers at ORCC under the direction of Dr Barbara Vanderhyden, have developed the expertise for evaluating drugs to treat ovarian cancers. Under the collaboration, Arius will match their anti-cancer antibodies to different types of ovarian cancer and ORCC will then test the antibodies in their models for drug efficacy.

“Ovarian cancer is an area where there is a major need for new, effective treatments," says Dr David Young, president and chief scientific officer with Arius. "We have seen some indications that a number of our antibodies act against one type of ovarian cancer and we are very pleased to be working with ORCC and Dr Vanderhyden to expand this work in their validated models of cancer.”